Oct 16 (Reuters) – Shah Capital, one of Novavax's top shareholders, said on Friday it no longer seeks to influence control of the vaccine maker after restructuring into a family office. • The investor
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)